Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate
Portfolio Pulse from Vandana Singh
Biogen has terminated its collaboration with Sage Therapeutics for the SAGE-324 program after negative Phase 2 study results for treating essential tremor. Sage will regain full ownership of SAGE-324 and may explore other indications. The partnership on Zurzuvae for postpartum depression continues.
September 26, 2024 | 2:38 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Biogen terminates its collaboration with Sage on SAGE-324 after negative trial results. The company continues its partnership with Sage on Zurzuvae for postpartum depression.
Biogen's decision to terminate the collaboration on SAGE-324 reflects the negative trial results, but the continuation of the partnership on Zurzuvae mitigates the impact, resulting in a neutral short-term outlook.
CONFIDENCE 90
IMPORTANCE 60
RELEVANCE 70
NEUTRAL IMPACT
Sage Therapeutics regains full ownership of SAGE-324 after Biogen ends collaboration due to negative trial results. Sage may explore other indications for SAGE-324.
The termination of the collaboration with Biogen on SAGE-324 is significant for Sage as it regains full control over the asset. However, the negative trial results limit immediate positive impact, leading to a neutral short-term outlook.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80